Hashishi

GW Pharma, Bayer get Canadian approval for cannabis-based Sativex in cancer pain
8-7-'07 | Hemscott

LONDON (Thomson Financial) - GW Pharmaceuticals PLC and Bayer AG's unit Bayer Inc said they have received Canadian regulatory conditional approval for Sativex, a cannabis-derived therapy, for advanced cancer pain treatment.

The approval has conditions attached to it, and UK-based AIM listed GW Pharmaceuticals said the approval reflects the 'promising nature of the clinical evidence which will be confirmed with further studies'.

Data from current studies show Sativex achieved a statistically significant improvement in pain relief, in comparison with placebo, the compnay said.

Sativex, the only pharmaceutical product derived from components of the cannabis plant, is administered through a spray pump under the tongue or on the inside of the cheek allowing a more flexible dosing than an oral tablet, GW added.

__________________